.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean consequence of 11 months, people along with metastatic intestinal lumps that got biomarker-matched treatments based on distributing cyst DNA profiling revealed a better medical advantage than those receiving unrivaled treatment.